NCT00637741已完成4 期
Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 4
- 主要终点
- Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR
研究概览
简要总结
The objective of this clinical investigation is to evaluate the long-term (up to 12 months) outcome of the 200 mm long self-expanding nitinol EverFlex (ev3) stent in long femoropopliteal lesions (TASC C & D) Is is the first time that the use of 200 mm long stents will be evaluated in these lesions. It is expected that the outcome of the treatment with this type of long stents will be better as the treatment of identical lesions lengths with multiple shorter stents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •De novo, restenotic or reoccluded lesion located in the femoropopliteal arteries suitable for stenting
- •Patient presenting a score from 2 to 5 following Rutherford classification
- •Patient is willing to comply with specified follow-up evaluations at the specified times
- •Patient is >18 years old
- •Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- •Prior to enrollment, the guidewire has crossed target lesion
- •Patient is eligible for treatment with the self-expanding nitinol EverFlex (ev3) stent
- •ANGIOGRAPHIC
- •The target lesion is located within the native femoropopliteal artery until maximally 3 cm proximally of the knee joint.
- •The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation
- •The target lesion, visually estimated, has a minimal length of 15 cm and can be categorized as either a type C or D lesions according the TASC II guidelines
- •Target vessel diameter visually estimated is >4mm and <6.5 mm
- •There is angiographic evidence of at least one-vessel-runoff to the foot
排除标准
- •Presence of another stent in the target vessel that was placed during a previous procedure
- •Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis
- •Previous by-pass surgery in the same limb
- •Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
- •Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
- •Perforation at the angioplasty site evidenced by extravasation of contrast medium
- •Patients with known hypersensitivity to nickel-titanium
- •Patients with uncorrected bleeding disorders
- •Aneurysm located at the level of the SFA
- •Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
- •Life expectancy of less than twelve months
- •Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis > 30% or ipsilateral iliac treatment conducted after the target lesion procedure
- •Use of thrombectomy, artherectomy or laser devices during procedure
- •Any planned surgical intervention/procedure within 30 days of the study procedure
- •Any patient considered to be hemodynamically unstable at onset of procedure
- •Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
结局指标
主要结局
Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR
时间窗: 12 months
次要结局
- Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex imaging.(procedure)
- Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR(6 months)
- Clinical success at follow-up defined as an improvement of Rutherford classification of one class or more as compared to the pre-procedure(6 & 12 months)
- Stent fracture rate determined on x-ray (Mild - single strut fracture; Moderate - fracture of more than one strut but without complete separation; Severe - complete separation)(12 months)
- Serious adverse events(12 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
4 期
Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease With the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing With 4EVER Trial Results)Peripheral Vascular DiseaseNCT02211664Flanders Medical Research Program120
已完成
2 期
a Physician-inititated Trial Investigating the iVolution Nitinol StentPeripheral Arterial DiseaseNCT02430922Flanders Medical Research Program120
已完成
2 期
Drug Eluting Stents In The Critically Ischemic Lower Leg 2Peripheral Arterial DiseaseNCT01442636Flanders Medical Research Program60
进行中（未招募）
不适用
MOTIV Bioresorbable Scaffold in BTK Artery DiseaseCritical Limb IschemiaPeripheral Arterial DiseaseNCT03987061Dr. Sabrina Overhagen58
终止
3 期
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).Depressive Episodes, Bipolar I DepressionNCT05227209Sumitomo Pharma America, Inc.64